Product Description
CFI-402411 is a novel, highly orally available immunomodulatory small molecule inhibitor of HPK1 (Hematopoietic Progenitor Kinase 1), a critical regulator of immune cell activation, antigen presentation, and T cell responses to immunosuppressive factors
Mechanisms of Action: HPK1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Treadwell Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Hong Kong, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04521413 |
TWT-101 | P2 |
Active, not recruiting |
Oncology Solid Tumor Unspecified |
2025-11-01 |
12% |
2025-05-22 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/20/2024 |
News Article |
Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia |
|
12/15/2023 |
News Article |
Treadwell Therapeutics Announces a Presentation at the 2023 ASH Annual Meeting and Advisory Board Meeting |
|
12/06/2023 |
News Article |
Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions |
|
02/03/2023 |
News Article |
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer |